HRP20161389T1 - Derivati pantotenata namijenjeni liječenju neuroloških poremećaja - Google Patents

Derivati pantotenata namijenjeni liječenju neuroloških poremećaja Download PDF

Info

Publication number
HRP20161389T1
HRP20161389T1 HRP20161389TT HRP20161389T HRP20161389T1 HR P20161389 T1 HRP20161389 T1 HR P20161389T1 HR P20161389T T HRP20161389T T HR P20161389TT HR P20161389 T HRP20161389 T HR P20161389T HR P20161389 T1 HRP20161389 T1 HR P20161389T1
Authority
HR
Croatia
Prior art keywords
compound
intended
compound according
subject
treatment
Prior art date
Application number
HRP20161389TT
Other languages
English (en)
Croatian (hr)
Inventor
Andrew Vaino
Marek BIESTEK
Martin SHKRELI
Original Assignee
Retrophin, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Retrophin, Inc. filed Critical Retrophin, Inc.
Publication of HRP20161389T1 publication Critical patent/HRP20161389T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/242—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyaryl compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/222—Amides of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
HRP20161389TT 2012-04-27 2013-04-26 Derivati pantotenata namijenjeni liječenju neuroloških poremećaja HRP20161389T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261639602P 2012-04-27 2012-04-27
PCT/US2013/038458 WO2013163576A1 (en) 2012-04-27 2013-04-26 Pantothenate derivatives for the treatment of neurologic disorders
EP13722201.4A EP2841438B1 (en) 2012-04-27 2013-04-26 Pantothenate derivatives for the treatment of neurologic disorders

Publications (1)

Publication Number Publication Date
HRP20161389T1 true HRP20161389T1 (hr) 2016-12-02

Family

ID=48428654

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20161389TT HRP20161389T1 (hr) 2012-04-27 2013-04-26 Derivati pantotenata namijenjeni liječenju neuroloških poremećaja
HRP20190038TT HRP20190038T1 (hr) 2012-04-27 2019-01-04 Derivati pantotenata namijenjeni liječenju neuroloških poremećaja

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20190038TT HRP20190038T1 (hr) 2012-04-27 2019-01-04 Derivati pantotenata namijenjeni liječenju neuroloških poremećaja

Country Status (24)

Country Link
US (3) US8673883B2 (enExample)
EP (3) EP2841438B1 (enExample)
JP (3) JP6254151B2 (enExample)
KR (1) KR20150035550A (enExample)
CN (2) CN106977544B (enExample)
AU (3) AU2013251345B2 (enExample)
BR (1) BR112014026817A2 (enExample)
CA (1) CA2879314A1 (enExample)
CY (2) CY1118198T1 (enExample)
DK (2) DK3112372T3 (enExample)
ES (2) ES2600179T3 (enExample)
HR (2) HRP20161389T1 (enExample)
HU (2) HUE042199T2 (enExample)
IN (1) IN2014DN09584A (enExample)
LT (2) LT2841438T (enExample)
MX (1) MX360149B (enExample)
PL (2) PL2841438T3 (enExample)
PT (2) PT2841438T (enExample)
RS (2) RS58336B1 (enExample)
RU (2) RU2653497C2 (enExample)
SI (2) SI2841438T1 (enExample)
SM (2) SMT201900007T1 (enExample)
TR (1) TR201819263T4 (enExample)
WO (1) WO2013163576A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2879314A1 (en) * 2012-04-27 2013-10-31 Retrophin, Inc. Pantothenate derivatives for the treatment of neurologic disorders
WO2015061792A1 (en) 2013-10-25 2015-04-30 Retrophin, Inc. Panothenate derivatives for the treatment of neurological disorders
EP2868662A1 (en) 2013-11-04 2015-05-06 Acies Bio d.o.o. Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds
CN108473519A (zh) * 2015-12-08 2018-08-31 雷特罗芬公司 用于治疗神经疾病的环状磷酸酯和环状氨基磷酸酯
MX2019009342A (es) * 2017-02-07 2019-10-02 Retrophin Inc Formulaciones de fosmetpantotenato solido.
US12065404B2 (en) 2022-03-18 2024-08-20 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2676976A (en) 1950-12-04 1954-04-27 Nat Res Dev Synthesis of pantothenic acid-4' phosphate
US2870188A (en) 1955-10-03 1959-01-20 Hoffmann La Roche Process for the manufacture of pantothenic acid 4'-phosphate and its salts
RU2002110463A (ru) * 1999-09-21 2004-02-27 Басф Акциенгезелльшафт (De) Способ и микроорганизмы для получения пантосоединений
WO2003008626A2 (en) 2001-07-20 2003-01-30 Oregon Health And Science University Novel human nucleic acids encoding a pantothenate kinase and methods of use
DK1520030T3 (da) * 2002-07-03 2012-02-27 Basf Se Microorganismer og fremgangsmåder til forøget produktion af pantothenat
CN101287472B (zh) 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物
CA2879314A1 (en) * 2012-04-27 2013-10-31 Retrophin, Inc. Pantothenate derivatives for the treatment of neurologic disorders

Also Published As

Publication number Publication date
EP2841438B1 (en) 2016-08-10
EP2841438A1 (en) 2015-03-04
CN104520307A (zh) 2015-04-15
BR112014026817A2 (pt) 2017-07-18
JP6560284B2 (ja) 2019-08-14
SI3112372T1 (sl) 2019-04-30
HK1207863A1 (en) 2016-02-12
EP3112372A1 (en) 2017-01-04
SMT201900007T1 (it) 2019-02-28
CN106977544B (zh) 2019-06-07
JP2015515496A (ja) 2015-05-28
PL2841438T3 (pl) 2017-08-31
JP2017141257A (ja) 2017-08-17
RU2014147739A (ru) 2016-06-20
CY1118198T1 (el) 2017-06-28
US8673883B2 (en) 2014-03-18
SI2841438T1 (sl) 2016-12-30
RS58336B1 (sr) 2019-03-29
CN106977544A (zh) 2017-07-25
KR20150035550A (ko) 2015-04-06
US20160015727A1 (en) 2016-01-21
PT3112372T (pt) 2019-01-17
MX2014013048A (es) 2015-04-10
CN104520307B (zh) 2016-12-21
ES2600179T3 (es) 2017-02-07
MX360149B (es) 2018-10-24
CA2879314A1 (en) 2013-10-31
RS55319B1 (sr) 2017-03-31
JP2019206553A (ja) 2019-12-05
HRP20190038T1 (hr) 2019-02-22
LT3112372T (lt) 2019-01-10
LT2841438T (lt) 2016-11-10
CY1121238T1 (el) 2020-05-29
AU2013251345A1 (en) 2014-11-27
AU2017239508B2 (en) 2019-05-23
US9181286B2 (en) 2015-11-10
WO2013163576A1 (en) 2013-10-31
ES2708813T3 (es) 2019-04-11
DK2841438T3 (en) 2016-11-28
PT2841438T (pt) 2016-11-22
AU2017239508C1 (en) 2019-11-07
RU2018112720A (ru) 2019-02-28
SMT201600395B (it) 2017-01-10
EP3489248A1 (en) 2019-05-29
AU2013251345B2 (en) 2017-08-31
US20130289001A1 (en) 2013-10-31
RU2653497C2 (ru) 2018-05-10
US20140135294A1 (en) 2014-05-15
EP3112372B1 (en) 2018-11-07
TR201819263T4 (tr) 2019-01-21
HUE029474T2 (en) 2017-02-28
PL3112372T3 (pl) 2019-05-31
JP6254151B2 (ja) 2017-12-27
AU2019219733A1 (en) 2019-09-05
DK3112372T3 (en) 2019-02-18
AU2017239508A1 (en) 2017-10-26
HUE042199T2 (hu) 2019-06-28
IN2014DN09584A (enExample) 2015-07-17
US9629862B2 (en) 2017-04-25
AU2017239508B9 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
JOP20200222A1 (ar) أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
HRP20140011T1 (hr) Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja
HRP20161389T1 (hr) Derivati pantotenata namijenjeni liječenju neuroloških poremećaja
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
ME02910B (me) Spojevi tetrahidropirolotiazina
CA2925624C (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
EA201791239A8 (ru) ТЕТРАГИДРОПИРИДО[3,4-b]ИНДОЛОВЫЕ МОДУЛЯТОРЫ ЭСТРОГЕНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
EP2958486A4 (en) DEVICE FOR ENABLING PATIENT SICKNESS TESTS AND TREATMENT INDIVIDUAL MANAGEMENT, AND SYSTEM WITH THE DEVICE FOR MANAGING HEALTH CARE FOR A PATIENT
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
HRP20181048T1 (hr) Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
MY167423A (en) Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use
HRP20171512T1 (hr) Derivati betulina
MX358172B (es) Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson.
RU2017105353A (ru) Соединения
IL233557A0 (en) Use of lequinimod for the treatment of Crohn's disease in which the anti-TN-AP alpha treatment has failed
WO2013166037A9 (en) Non-retinoid antagonists for treatment of eye disorders
MA37455A1 (fr) Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique
HRP20171515T1 (hr) Spojevi fenoksietilpiperidina
EA201290694A1 (ru) Сульфонамидные производные 3,4-диарилпиразолов в качестве ингибиторов протеинкиназы
JO3128B1 (ar) بيبرازينو-3-فينيل-اندانيس معالج بالديتوريوم لمعالجة انفصام الشخصية- 1